Tevogen Inc

TVGN

Valor de mercado US$ 46 mi

WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”).

WARREN, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biopharma, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with HRK Healthcare LLC (“HRK”).

WARREN, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Tevogen Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), an integrated healthcare enterprise combining biotechnology, artificial intelligence, and healthcare services to improve the affordability and accessibility of life-saving medicines, today announced that it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”)on September 29, 2026, confirming that the Company had regained compliance with the $50 million minimum market value of listed securities requirement under Nasdaq Listing Rule 5450(B)(2)(A) for continued listing on The Nasdaq Global Market.

WARREN, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it will operate under the name Tevogen Inc., following approval by its Board of Directors.

WARREN, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) announced that its 2026 Annual Meeting of Stockholders (the “Annual Meeting)” is scheduled for Monday, August 24, 2026.

William Keane Appointed Interim Head of Initiative, Evaluating Potential Management Services Organization and Contract Research Organization Acquisitions WARREN, N.J., June 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the formation of its healthcare services initiative, a strategic business area intended to support the Company's evolution into a broader, revenue-generating healthcare enterprise.

WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced continued progress across its strategic acquisition initiatives intended to complement its existing business and support long-term financial self-sufficiency, which, if consummated, could realize approximately $100 million in combined annual revenue.

WARREN, N.J., May 21, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter of Intent (“LoI”) to evaluate a potential transaction with a Management Services Organization (“MSO”).

Tevogen highlights improved operating performance, disciplined capital allocation, pipeline growth, and evaluation of revenue-generating acquisitions.

WARREN, N.J., May 12, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a securities purchase agreement for a private investment in public equity (the “PIPE”) financing with existing investor The Patel Family, LLP for gross proceeds of $3 million.